Streptokinase Karma

Streptokinase Karma



Karma Pharmatech


Idaman Pharma
Concise Prescribing Info
Systemic administration in acute transmural MI not >12 hr w/ persistent ST-segment elevation or recent left bundle-branch block, DVT not >14 days, acute massive pulmonary embolism, acute & subacute peripheral arteries thromboses, chronic occlusive arterial diseases not >6 wk, central retinal artery or vein occlusion (arterial occlusions not >6-8 hr, venous occlusions not >10 days). Local administration in acute MI for re-opening of coronary vessels not >12 hr, acute, subacute & chronic thromboses as well as peripheral venous & arterial vessel embolisms.
Dosage/Direction for Use
Short-term lysis for acute MI Systemic 1,500,000 IU w/in 60 min. Local 20,000 IU intracoronary bolus. Maintenance: 2,000-4,000 IU/min over 30-90 min. Short-term thrombolysis adult w/ peripheral venous & arterial vessel occlusions/embolisms Systemic Initially 250,000 IU w/in 30 min, followed by maintenance: 1,500,000 IU/hr over max: 6 hr. Long-term lysis for peripheral occlusions Initially 250,000 IU w/in 30 min, followed by maintenance: 100,000 IU/hr. Max duration: 5 days. Acute, subacute & chronic peripheral thromboses & embolisms Local 1,000-2,000 IU in 3-5 min intervals up to 3 hr at total max dose: 120,000 IU. Central retinal vessels thromboses Systemic Max duration of therapy: 24 hr for arterial occlusion; 72 hr for venous occlusion. Interrupt therapy for 1 day, followed by homologous fibrinolytic administration if continuation of thrombolysis is indicated due to extensive thrombotic occlusions.
Hypersensitivity. Existing or recent internal haemorrhage; all forms of reduced blood coagulability, in particular spontaneous fibrinolysis & extensive clotting disorders; recent CVA, intracranial or intraspinal surgery; intracranial neoplasm; recent head trauma; arteriovenous malformation or aneurysm; known neoplasm w/ risk of haemorrhage; acute pancreatitis; uncontrollable HTN w/ systolic values >200 mmHg &/or diastolic values >100 mmHg or hypertensive retinal changes grades III/IV; recent vessel prosthesis implantation; simultaneous or recent treatment w/ oral anticoagulants (INR >1.3); endocarditis or pericarditis; known haemorrhagic diathesis; recent major op (6th-10th post-op day, depending on extent of the procedure); invasive op eg, recent organ biopsy, long-term (traumatic) closed chest cardiac massage. Severe hepatic or renal damage.
Special Precautions
Not indicated for patency restoration of IV catheters. Severe bleeding eg, intracranial haemorrhage; procedures & management of arterial/venous puncture; recent severe GI bleeding eg, active peptic ulcer; risk of severe local haemorrhage eg, in case of translumbar aortography; recent trauma & cardiopulmonary resuscitation; invasive op eg, recent intubation; puncture of non-compressible vessels, IM inj, large arteries; urogenital tract diseases w/ existing or potential bleeding sources (implanted bladder catheter); known septic thrombotic disease; severe arteriosclerotic vessel degeneration, cerebrovascular diseases; cavernous pulmonary diseases eg, open TB or severe bronchitis; mitral valve defects or atrial fibrillation; aortic dissection; diabetic retinopathy. Recent streptococcal infections eg, streptococcal pharyngitis, acute rheumatic fever & glomerulonephritis. Antistreptokinase Ab development; pre-treatment w/ heparin or coumarin derivatives. Perform mandatory & frequent haematological tests eg, blood coagulation tests. Administer corticosteroids prophylactically to reduce infusion-related allergic reactions. Recent abortion or delivery. Not to be used during pregnancy. Lactation. Elderly.
Adverse Reactions
Antistreptokinase Ab development; heart rate & rhythm disorders, angina pectoris. Inj site haemorrhage, ecchymoses, GI & genitourinary bleeding, epistaxis; allergic anaphylactic reactions eg, rash, flushing, itching, urticaria, angioneurotic oedema, dyspnoea, bronchospasm, hypotension; tachycardia, bradycardia; recurrent ischaemia, heart failure, reinfarction, cardiogenic shock, pericarditis, pulmonary oedema; nausea, diarrhoea, epigastric pain, vomiting; headache, back & musculoskeletal pain, chills, fever, asthenia, malaise; transient serum transaminases & bilirubin elevations.
Drug Interactions
Increased risk of haemorrhage w/ anticoagulants eg, heparin or drugs inhibiting platelet formation or function eg, platelet aggregation inhibitors, dextrans.
MIMS Class
Anticoagulants, Antiplatelets & Fibrinolytics (Thrombolytics)
ATC Classification
B01AD01 - streptokinase ; Belongs to the class of enzymes. Used in the treatment of thrombosis.
Streptokinase Karma powd for infusion (vial) 1,500,000 IU
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in